DAK-GESUNDHEIT has floated a tender for Contract notice: Pharmaceutical products. The project location is Germany and the tender is closing on 05 Jul 2018. The tender notice number is 271790-2017, while the TOT Ref Number is 14864128. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Expired Tender

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 05 Jul 2018

Other Information

Notice Type : Tender

TOT Ref.No.: 14864128

Document Ref. No. : 271790-2017

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : DAK-GESUNDHEIT
Office Name: DAK-Gesundheit
Address: Nagelsweg 27-31
Town: Hamburg
Postal Code: 20097


Phone: +49 402396-2682
Fax: +49 402396-3661
Germany
Email :vergabestelle@dak.de
URL :www.dak.de

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Lowest price
CPV code: 33600000, 33600000
CPV Description: Pharmaceutical products.

Completion of a non-exclusive discount agreement pursuant to - 130a para. 8 SGB V to the active substance Pegfilgrastim, ATC L03AA13, for the period v. [Reference number: 1001818 - Pegfilgrastim] - 130a Paragraph 8 SGB V allows the health insurance companies and pharmaceutical companies to carry out framework agreements on the costs of statutory sickness insuranceEnkassen. With regard to the statutory provisions governing the award of public contracts, a regular process of active substance-related, competitive tendering procedure is carried out by DAK-Gesundheit according to the regulations of the fourth part of the GWB. For medicinal products to be designated by the tenderer in Annex 2 to the contract to the above mentioned medicinal product, -Active substance (Pegfilgrastim, ATC L03AA13), DAK Health intends to conclude drug discounts with the latest pharmaceutical sales contracts with the largest possible pharmaceutical companies. A discount agreement i. R. d. Admission model to the above. Active substance enters into force for the first time on 1.9.2017 and ends on 31.8.2018 (2x6 months option). It endsDAK-G assumes that this procedure does not fall within the scope of the antitrust law because of the lack of a selection decision and the non-discriminatory accessibility of all pharmaceutical companies. It shall automatically terminate automatically with the entry into force of the exclusive contract-Pegfilgrastim, ATC L03AA13, as a result of a procurement procedure under the regulations of Part Four of the GWB with one or more contracting parties. In order to meet the diversity of potential contract partners within the framework of the licensing model, each pharmaceutical company will be required to conclude a framework contract at any time and at the same time during the contract periodTions. The necessary contract documents are available via the online portal www.dtvp.de/center under the I.3., As well as the subsequent entry into the agreements which enter into force for the first time on September 1, 1917, the complete and timely transmission of the following proofs / explanations / attachments (erhaCan be downloaded from the I.3. ) To the following contact person at DAK-G:

1. Letter of Offer

2nd Current proof of entry in the professional or commercial register (see III.1.1.)

3. Declaration by the company (Annex A1) that none of the exclusion criteria is in accordance with -- 123, 124 GWB (see III.1.1.). Declare that forThose medicinal products for which the interested party wishes to conclude a contract under this procedure, is subject to authorization under the law on medicinal products, and that the tenderer is entitled to sell (Annex A2) (see III.1.1. Declaration by the company that the statutory provisions on the minimum wage and tariff refusal are observed and complied with (Annex A3)-(See III.1.1.). Recognition of the contractual provisions of the DAK health, in particular also of the specified discounts by signing the contract stamped with a company stamp (2 times in the original) by the interested party in the designated place. The completed enclosures 1 and 2 to the contract (2-fold in the original). The interested party here has the drugs to the above. workestOff, which should be the object of the contract. (DAK-Gesundheit,

Mariam Shirdel (0042 60),

Nagelsweg 27-31,

. The documents are to be submitted by post to: 20097 Hamburg.

In addition, Attachment 2 is to be sent as an excel file to the mail address am_rabattvertraege@dak.de. Contracts in the-Framework of this model and to the above. Active substance will be concluded for the first time with effect from 1 July 2017 and end on 31.8.2018. The contract can be extended by the DAK-G twice as often as six months. Interested parties wishing to become contractors on this date have the documents to be submitted by the 5th of the previous month, Position. It comes hiTo ensure timely access to DAK health. Later accessions are possible at any time. In order to be able to join during the term of the contract on the 1st or 15th of the following month, the above- Documents, irrespective of the desired accession, of the DAK health up to the 5th of the previous month. This also applies to the timely access of both DAK-Gs. Example:-The applicant should be admitted to the 15.7.20xx (follow-up), the documents must be available by 5.6.20xx (previous month). Note: The publication is made here using the form for open procedures. As already made clear, this is not such a notice had to be used for technical reasons, since it keIn form suitable for approval procedures. Current proof of entry in the professional or trade register (not more than 6 months in the case of dispatch) in accordance with the legislation of the country in which the company is resident, Eg current commercial register extract; Copy is sufficient.

2. Declaration of the company that none of the exclusion criteria according to ---123, 124 GWB is present. To this end, the A1 is to be signed, to be stamped with the company stamp and to be submitted in the original. Declaring that medicinal products for which the interested party wishes to conclude a contract under this procedure are subject to authorization under the law of medicinal products and that the tenderer is entitled to sell them at the start of the contract (AnnexA2) (see III.1.1.). Declaration of the company that the statutory provisions on the minimum wage and the tariff refusal are observed and complied with (Annex A3). For this purpose, A3 is to be signed, stamped with a company stamp and submitted in original form.

DAK Health has a so-called pre-qualification procedure for pharmaceutical companies through the European publicity platform(EU Notice No 2015 / S 105-190319 of 3 June 2015), which has been published for the simplified participation in future drug discounts. If the bidder has received an effective pre-qualification notice from the DAK health in good time before submission of the dossier, he needs the company-specific proof of suitability (proof of the entry in the professional or vocational qualification)-Commercial register, the company's own declaration that none of the exclusion criteria pursuant to Art. -- 123, 124 GWB, safety certificate of the statutory health insurance fund) with copy and annex of the prequalification certificate in copy no more. Annex A2 is to be added in all cases. The pre-qualification notice of the DAK health also serves as NIn the case of open-house procedures of DAK health, irrespective of the value of the contract.

Declaration that the medicinal products for which the interested party wishes to conclude the contract in the Rahmendieses procedure are subject to authorization under the drug law and that the tenderer is responsible for the distribution Is justified. For this purpose, the enclosure A2 has to be signed with the companyAnd submit it in the original. DAK Health has published a so-called pre-qualification procedure for pharmaceutical companies for the simplified participation in future drug discounts (EU notice 2015 / S 105-190319 of 3.6.2015) via the European Notification Center. If the bidder submits the documents e(Proof of the entry in the professional or trade register, the company's own declaration that none of the exclusion criteria according to -- 123, 124 GWB is present, certificate of harmlessness of the statutory health insurance fund) With reference and addition of the PraequalIn copy no longer be attached. Annex A2 is to be added in all cases. The DAK health pre-qualification certificate also serves as a proof for open-house DAK health procedures.

The contract documents can also be sent by e-mail in the case of the DAK health mentioned in I.1. Must be requested. The tender documents will be(By means of the bidder communication via the award portal dtvp.de) or in individual cases by e-mail or in writing (by means of a fax or letter) to the members listed under I. 1. Contact point. They are to be formulated in German. Answers will be given to all entrepreneurs, Ie requesting the tender documents by means of a registration, in an anonymous form. In doing so, the answers are made available to the entrepreneurs via bidder portal dtvp.de. Companies who have downloaded the tender documents without registration must, on their own responsibility, For this purpose, This publication is not a public procurement contract within the meaning of the Public Procurement Direc- tive Directive 2014/24 / EU of the European Parliament and of the Council and / or the right to rectify the dispute. In order to ensure the widest degree of transparency for the intended

contract conclusion, E Publication in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the procedure "open procedure", are solely due to the use of this publication form and to the publishing platformE Significance, in particular a submission of sub-regula- tory regulations, insofar as they are not compulsory for legal reasons, is not associated with this.

Notification ID: CXP4YM5YE7A.


Internet address (URL): www.dak.de
Directive: Classical Directive (2014/24/EU)

Documents

 Tender Notice